Fragment‐based Identification of Hsp90 Inhibitors
暂无分享,去创建一个
Mark Whittaker | Thomas Hesterkamp | Dirk Winkler | Oliver Barker | Ciro Mercurio | R. Cheng | S. Minucci | C. Mercurio | D. Winkler | M. Varasi | T. Hesterkamp | J. Barker | M. Whittaker | O. Ichihara | R. Boggio | Fulvia Fusar | John J Barker | Roberto Boggio | Viddhata Chauhan | Robert K Y Cheng | Vincent Corden | Stephen M Courtney | Neil Edwards | Virginie M Falque | Fulvia Fusar | Mihaly Gardiner | Estelle M N Hamelin | Osamu Ichihara | Richard S Jones | Owen Mather | Saverio Minucci | Christian A G N Montalbetti | Annett Müller | Deepti Patel | Banu G Phillips | Mario Varasi | Christopher J Yarnold | C. Yarnold | C. Montalbetti | Virginie M. Falque | D. Patel | S. Courtney | E. Hamelin | Oliver Barker | V. Corden | N. Edwards | A. Müller | M. Gardiner | O. Mather | V. Chauhan | Richard S. Jones | Banu G. Phillips | Richard S. Jones | Richard S. Jones | Annett Müller
[1] R. Glen,et al. Molecular recognition of receptor sites using a genetic algorithm with a description of desolvation. , 1995, Journal of molecular biology.
[2] Natalie G Ahn,et al. Proteomics and genomics: perspectives on drug and target discovery , 2008, Current Opinion in Chemical Biology.
[3] L. Neckers,et al. The Heat Shock Protein 90 Antagonist Novobiocin Interacts with a Previously Unrecognized ATP-binding Domain in the Carboxyl Terminus of the Chaperone* , 2000, The Journal of Biological Chemistry.
[4] L. Neckers,et al. Targeting the Molecular Chaperone Heat Shock Protein 90 Provides a Multifaceted Effect on Diverse Cell Signaling Pathways of Cancer Cells , 2007, Clinical Cancer Research.
[5] Brian Dymock,et al. Adenine derived inhibitors of the molecular chaperone HSP90-SAR explained through multiple X-ray structures. , 2004, Bioorganic & medicinal chemistry letters.
[6] L. Pearl,et al. Structure, function, and mechanism of the Hsp90 molecular chaperone. , 2001, Advances in protein chemistry.
[7] B. Blagg,et al. Hsp90 as a Target for Drug Development , 2006, ChemMedChem.
[8] Jie Ge,et al. Development of 17-allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against Hsp90 , 2006, Proceedings of the National Academy of Sciences.
[9] Jason C. Young,et al. The heat shock protein 90-targeting drug cisplatin selectively inhibits steroid receptor activation. , 2003, Molecular endocrinology.
[10] S. Ramalingam,et al. Phase I and Pharmacodynamic Study of 17-(Allylamino)-17-Demethoxygeldanamycin in Adult Patients with Refractory Advanced Cancers , 2007, Clinical Cancer Research.
[11] R. Gilbertson,et al. A Phase I Study of 17-Allylaminogeldanamycin in Relapsed/Refractory Pediatric Patients with Solid Tumors: A Children's Oncology Group Study , 2007, Clinical Cancer Research.
[12] X. Barril,et al. Structure-based discovery of a new class of Hsp90 inhibitors. , 2005, Bioorganic & medicinal chemistry letters.
[13] S. Larson,et al. Phase I Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients with Advanced Cancer , 2007, Clinical Cancer Research.
[14] L. Neckers,et al. The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin , 1998, Cancer Chemotherapy and Pharmacology.
[15] James R. Porter,et al. Design, synthesis, and biological evaluation of hydroquinone derivatives of 17-amino-17-demethoxygeldanamycin as potent, water-soluble inhibitors of Hsp90. , 2006, Journal of medicinal chemistry.
[16] Chrisostomos Prodromou,et al. Structural and functional analysis of the middle segment of hsp90: implications for ATP hydrolysis and client protein and cochaperone interactions. , 2003, Molecular cell.
[17] S. Lakhani,et al. Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] Mark Whittaker,et al. Fragment-based activity space: smaller is better. , 2008, Current opinion in chemical biology.
[19] J. Sloan,et al. Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] T. Hesterkamp,et al. Fragment based drug discovery using fluorescence correlation: spectroscopy techniques: challenges and solutions. , 2007, Current topics in medicinal chemistry.
[21] P. Schenone,et al. Reaction of 2-dimethylaminomethylene-1,3-diones with dinucleophiles. III. Synthesis of 5-acylpyrimidines and 7,8-dihydroquinazolin-5(6H)-ones: Reaction of 2-Dimethylaminomethylene-1,3-diones with Dinucleophiles. III , 1983 .
[22] Mike Wood,et al. 4,5-diarylisoxazole Hsp90 chaperone inhibitors: potential therapeutic agents for the treatment of cancer. , 2007, Journal of medicinal chemistry.
[23] Sarat Chandarlapaty,et al. SNX2112, a Synthetic Heat Shock Protein 90 Inhibitor, Has Potent Antitumor Activity against HER Kinase–Dependent Cancers , 2008, Clinical Cancer Research.
[24] L. Fritz,et al. A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors , 2003, Nature.
[25] D. Solit,et al. Development and application of Hsp90 inhibitors. , 2008, Drug discovery today.
[26] R. Arceci,et al. Phase I Pharmacokinetic and Pharmacodynamic Study of 17-N-Allylamino-17-Demethoxygeldanamycin in Pediatric Patients with Recurrent or Refractory Solid Tumors: A Pediatric Oncology Experimental Therapeutics Investigators Consortium Study , 2007, Clinical Cancer Research.
[27] L. Pearl,et al. NVP-AUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis. , 2008, Cancer research.